{"slideshow_credits": null, "snippet": "The agreements between Gilead Sciences and seven Indian firms seek to provide treatment to those infected in 91 developing nations.", "abstract": "Gilead Sciences, maker of one of costliest drugs in world, says it has struck deals with seven generic drug makers in India to sell lower-cost versions of Sovaldi, its hepatitis C medicine--a $1,000-a-pill treatment--in poorer countries; drug is on pace to exceed $10 billion in sales in 2014.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gardiner", "role": "reported", "lastname": "HARRIS", "rank": 1, "organization": ""}], "original": "By GARDINER HARRIS", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/09/16/business/international/maker-of-hepatitis-c-drug-strikes-deal-on-generics-for-poor-countries.html", "lead_paragraph": "The agreements between Gilead Sciences and seven Indian firms seek to provide treatment to those infected in 91 developing nations.", "headline": {"main": "Maker of Costly Hepatitis C Drug Sovaldi Strikes Deal on Generics for Poor Countries", "print_headline": "Deal Struck on Generics of Costly Hepatitis C Drug"}, "_id": "5416be8b38f0d85fde323f29", "word_count": "1231", "multimedia": [{"height": 126, "url": "images/2014/09/16/business/16hepatitis-pic2/16hepatitis-pic2-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/09/16/business/16hepatitis-pic2/16hepatitis-pic2-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 472, "url": "images/2014/09/16/business/16hepatitis-pic2/16hepatitis-pic2-articleLarge.jpg", "legacy": {"xlarge": "images/2014/09/16/business/16hepatitis-pic2/16hepatitis-pic2-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "472"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/09/16/business/16hepatitis-pic2/16hepatitis-pic2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/09/16/business/16hepatitis-pic2/16hepatitis-pic2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-09-16T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Sovaldi (Drug)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Hepatitis", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Gilead Sciences Inc", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Third World and Developing Countries", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Alton, Gregg H", "name": "persons", "is_major": "N", "rank": "6"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": "International Business", "type_of_material": "News"}